


PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19

GÁZQUEZ-PÉREZ, R., GÁMEZ-TORRES, D., SÁNCHEZ-VARELA, M., SÁNCHEZ-RODRÍGUEZ, B., GÓMEZ-SÁNCHEZ, MT., MORENO-DÍAZ, T.
HOSPITAL UNIVERSITARIO TORRECÁRDENAS, PHARMACY. ALMERÍA. SPAIN



BACKGROUND AND IMPORTANCE

Cilgavimab/tixagevimab are recombinant human IgG1k monoclonal antibodies, which are indicated for COVID-19 pre-exposure prophylaxis in adults and adolescents ≥ 12 years of age weighing ≥ 40 kg.



AIM AND OBJETIVES

To assess patients who are potential candidates for treatment with cilgavimab/tixagevimab in a tertiary care hospital and to describe the search strategy



MATERIAL AND METHODS


In Spain, potential candidates for treatment with cilgavimab/tixagevimab are people with a high degree of immunosuppression (due to pathology or treatment) who do not respond adequately to vaccination. The Spanish Agency of Medicines and Health Products establishes the conditions for patients who are candidates for treatment with cilgavimab/tixagevimab¹. A search for patients was carried out, prioritizing the following criteria: hematological patients on treatment with rituximab during the last 9 months, patients with solid organ transplant, patients with multiple sclerosis on treatment with ocrelizumab/rituximab, and patients with recent infection by COVID-19 who belong to any risk group. All of them underwent serology, including in the study those with negative serology (anti-anati-S antibodies < 260 BAU/ml). Those patients were scheduled for cilgavimab/tixagevimab administration.



RESULTS

Positive serology (anti-anati-S antibodies > 260 BAU/ml) = 40

Unknown reasons = 7
COVID19 infection = 2
deep vein thrombosis suspected = 1



CONCLUSIONS AND RELEVANCE



More than half of the patients enrolled did not have an adequate response to COVID-19 vaccination. The search strategy was a good tool for administering pre-exposure prophylaxis of COVID-19 to these more vulnerable patients. Further studies are needed to evaluate the effectiveness of the treatment.

BIBLIOGRAFÍA: <https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%E2%80%99119/prevencion-frente-a-la-covid-19/personas-candidatas-a-recibir-evusheld-en-espana/#:~:text=En%20Espa%C3%B1a%2C%20son%20potenciales%20candidatas,responden%20adecuadamente%20a%20la%20vacunaci%C3%B3n.>

